secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001558370-24-011071
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q2 net loss narrows to $10.1M; cash $371M; anti-tau trial underway, data H1 2025
--------------------------------------------------------------------------------

- Q2 collaboration revenue $29.6M (vs $4.9M YoY); net loss $10.1M vs $22.2M loss a year earlier.
- Cash, equivalents and marketable securities at $371M as of June 30; runway into 2027.
- First participants dosed in Phase 1a SAD of anti-tau antibody VY7523; top-line safety/PK data expected H1 2025.
- Three gene therapy INDs on track for 2025: SOD1 ALS (VY9323), GBA1, and Friedreich's ataxia.
- Appointed Nathan Jorgensen as CFO; received $3M milestone from Neurocrine for GBA1 candidate selection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837024011071/0001558370-24-011071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837024011071/vygr-20240806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer